昂利康 (002940)
Zhejiang Anglikang Pharmaceutical Co.,Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 20172.82
- Circulating A-Shares(W): 18527.55
- Earnings Per Share(RMB): 0.3900
- Net Assets Per Share(RMB): 7.9012
- Operating Revenue(W RMB): 105516.46
- Total Profit(W RMB): 11251.57
- Net Profit Attributable to Parent(W RMB): 7768.99
- Net Profit Growth Rate(%): 55.59
- Weighted Return on Equity(%): 4.9900
- Operating Cash Flow Per Share(RMB): 0.9920
- Undistributed Profit Per Share(RMB): 3.4496
- Capital Reserve Per Share(RMB): 3.4724
2. Main Business
The main business covers:
- Chemical Active Pharmaceutical Ingredients
- Chemical Preparations
- Pharmaceutical Excipients
- R&D, production and sales of special intermediate series products
3. Company Basic Information
- Company Name: Zhejiang AngLiKang Pharmaceutical Co., Ltd.
- Listing Date: 2018-10-23
- Industry: Pharmaceutical Manufacturing
- Address: No. 1000, North Shengzhou Avenue, Shengzhou City, Zhejiang Province
- Website: www.alkpharm.com
- Company Profile: The issuer was established through the overall change of AngLiKang Co., Ltd. On November 21, 2014, the shareholders' meeting of AngLiKang Co., Ltd. passed a resolution, unanimously agreeing to change AngLiKang Co., Ltd. into a joint stock limited company. Based on the audited net assets of RMB 186,495,781.85 as of September 30, 2014, as stated in the audit report "Tianjian Audit [2014] No. 6521" issued by Tianjian Certified Public Accountants, the company was converted into 67.5 million shares at a conversion ratio of 1:0.3619, with the portion of net assets after deducting the share capital included in capital reserve. On December 9, 2014, Tianjian Certified Public Accountants issued the capital verification report "Tianjian Yan [2014] No. 267", verifying that all the capital contributions subscribed by the promoters had been fully paid. On December 18, 2014, AngLiKang completed the industrial and commercial establishment registration procedures at the Shaoxing Market Supervision Administration and obtained the "Business License of Enterprise Legal Person" with registration number 330683000017575. The legal representative is Fang Nanping, and the registered capital and paid-in capital are both RMB 67.5 million.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shengzhou Jun Tai Investment Co., Ltd. | General Legal Person | 7148.50 | 38.58 |
| 2 | Zhejiang AngLiKang Pharmaceutical Co., Ltd. - The First Phase Employee Stock Ownership Plan | Asset Management Plan | 433.12 | 2.34 |
| 3 | GF Healthcare Equity Securities Investment Fund Class A | Fund | 333.84 | 1.80 |
| 4 | China Europe Healthcare Hybrid Securities Investment Fund Class A | Fund | 308.63 | 1.67 |
| 5 | Fullgoal Precision Medical Flexible Allocation Hybrid Securities Investment Fund Class A | Fund | 259.35 | 1.40 |
| 6 | China Universal Innovation Pharmaceutical Theme Hybrid Securities Investment Fund Class A | Fund | 216.63 | 1.17 |
| 7 | Great Wall Pharmaceutical Industry Selection Hybrid Initiated Securities Investment Fund Class A | Fund | 174.21 | 0.94 |
| 8 | China Universal Medical Service Flexible Allocation Hybrid Securities Investment Fund Class A | Fund | 128.30 | 0.69 |
| 9 | Fullgoal Tiansheng Flexible Allocation Hybrid Securities Investment Fund | Fund | 74.87 | 0.40 |
| 10 | Fullgoal Robust Hengsheng 12-month Holding Period Hybrid Securities Investment Fund Class A | Fund | 62.96 | 0.34 |
5. Concept Sectors
- Vitamin
- Helicobacter Pylori
- Innovative Drugs
- Synthetic Biology
- Pet Economy
- Private Placement Plan
- Funds Reducing Holdings
- Special Loans
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information